Abstract: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases. There is provided a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint diseases, wherein methotrexate is conjugated with a carboxyl group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids.

Abstract: The invention provides novel compounds that may be used as intermediates in the preparation of epothilones, epothilone analogs and derivative, as well as new synthetic methods for producing the intermediates and products.

Abstract: A method for producing propylene oxide comprising a step of reacting hydrogen peroxide with propylene in the presence of an epoxidation catalyst in a liquid phase to produce propylene oxide and a step of recovering a recyclable constituent in a vent gas generated in the above step by absorbing the recyclable constituent in a solvent containing a nitrile.

Abstract: The invention relates to preparing derivatives of formula (1), wherein, in particular R1 and R2, identical or different, represent a hydrogen, flourine or chlorine atom, a hydroxy group, an alkyl radical and an alkoxy radical, R3 is an alkyl radical, a hydroxy group, or a methoxy radical, R4 is a hydrogen atom or a methyl radical and R5 and R6, identical or different, represent a hydrogen atom, an alkyl radical, an alkoxy radical, an alkylthio radical, and an alkylamino radical. The inventive method consists in reducing an amid of formula (9).

Abstract: The present invention relates to a process for producing glycidol from glycerol carbonate as a raw material with a high yield. The process for producing glycidol according to the present invention includes the steps of (1) reducing a content of a salt having a weak acidity in glycerol carbonate to 1500 ppm by mass or less; and (2) obtaining the glycidol from the glycerol carbonate.

Abstract: A synthesis of an energetic prepolymer used as a high-energy binder for an insensitive and high performance explosive is disclosed. More specifically, provided are a novel compound 2-nitratoethyl oxirane expressed by formula III, a novel compound poly(2-nitratoethyl oxirane) expressed by formula IV, obtained by polymerization of 2-nitratoethyl oxirane used as a monomer and a preparation method thereof. The compound, used as an energetic prepolymer and a monomer for preparation thereof can substitute for existing poly(glycidyl nitrate) (PGN) which has been known to be a promising one having the best performance among existing energetic prepolymers, but which has a problem to be self-decomposed after synthesis of polyurethane elastomer, to solve this problem.

Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.

Abstract: A method of making a compound of formula II comprising the reaction of a compound of formula RCONH2 with a compound of formula III R being a moiety having between 1 and 15 carbon atoms and optionally from 1 to 5 heteroatoms independently selected from oxygen, nitrogen and sulfur, and X and Y being independently selected front the group consisting of H, methyl, ethyl, OMe, OEt, and mixtures thereof; the reaction being performed in a solvent in the presence of a base. The method is useful for the inexpensive manufacture of certain commercially-valuable compounds, including some that have desirable cooling properties.

Abstract: A process for producing a titanium-containing silicon oxide catalyst, which comprises the following steps A and B; a catalyst obtainable by the process; and a process for producing an olefin oxide using the catalyst.

Abstract: The present invention relates to methods for the preparation and purification of mupirocin calcium. The process comprises adsorbing mupirocin to a hydrophobic adsorbent resin, exposing the bound mupirocin to a calcium-containing solution, washing impurities from the resin and eluting purified mupirocin calcium from the resin.

Abstract: The present invention relates to a process for producing glycidol from glycerol carbonate by subjecting the glycerol carbonate to decarboxylation reaction in the presence of a solvent containing no active hydrogen. In the process, glycidol can be produced from glycerol carbonate as a raw material of the glycidol with a high selectivity.

Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure trans-cyclopropane carboxylic acid derivatives, processes for preparing the carboxylic acid derivatives and their use in preparing pharmaceuticals.

Abstract: A novel tartaric acid salt of Isofagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.

Abstract: The present invention relates to a process for producing propylene oxide comprising (I) reacting propene with hydrogen peroxide in the presence of a catalyst to give a mixture (GI) comprising propylene oxide, unreacted propene, and oxygen; (II) separating propylene oxide from mixture (GI) to give a mixture (GII) comprising propene and oxygen; (III) reducing the oxygen comprised in mixture (GII) at least partially by reaction with hydrogen in the presence of a catalyst comprising Sn and at least one noble metal.

Abstract: The present invention relates to a method for producing propylene oxide, characterized in that peroxide is reacted with propylene in the presence of a titanosilicate catalyst which has an X-ray diffraction pattern of the values indicated below and is represented by the formula. xTiO2·(1?x)SiO2 (In the formula, x denotes a numerical value of 0.0001 to 0.1.) X-ray diffraction patterns (interplanar spacing of lattice d/?) 13.2±0.6 12.3±0.3 11.0±0.3 9.0±0.3 6.8±0.3 3.9±0.2 3.5±0.1 3.4±0.1.

Abstract: Disclosed herein is a method for purification of dianhydrides comprising a substantial amount (10000 ppm or more) of at least one metal salt. In one aspect the method is useful for the purification of dianhydrides prepared by the reaction of a halophthalic anhydride with a metal carbonate and may be optionally catalyzed by a phase transfer catalyst. The purification of the dianhydrides may be accomplished by hydrolyzing the dianhydride metal salt mixture directly to a tetraacid with an inorganic acid, followed by separating the impurities from an aqueous phase, and subsequently heating the tetraacid to effect ring closure to form a purified dianhydride having less than 50 parts per million metal halide and lower levels of other residual impurities. In one aspect the method is highly effective in removing phase transfer catalyst impurities such as hexalkylguanidinium halides initially present in the dianhydride undergoing purification.

Abstract: Cosmetic or dermatological compositions which comprise at least one piperidinium salt, preferably a 4-[(2-cyclopentyl-2-hydroxyphenylacetyl)oxy]-1,1-dimethyl-piperidinium salt, and the use thereof, particularly as antiperspirants. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Abstract: The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

Abstract: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.

Abstract: The invention relates to a neuroactive substance which is characterised in that it has formula (O), wherein R1, R2, R3 and R4 are identical or different and are methyl or ethyl radicals. Preferably, the neuroactive substance comprises 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hy-droxy-7R-acetoxydecahydro naphthalene which can be isolated from Rhytisma fulvum cnidaria. The inventive neuroactive substance can be used as a pharmacological reagent in research work and is also suitable for use in the fields of industry (insecticides) and health.